The Optimal Therapeutic Window for Nonbioartificial Liver Support in Acute-On-Chronic Liver Failure: A Meta-Analysis and Meta-Regression Based on Baseline MELD Score
Abstract
NBALS efficacy in ACLF remains controversial. We aimed to determine if a "therapeutic window" exists by stratifying clinical outcomes based on baseline Model for End-Stage Liver Disease (MELD) scores. We searched PubMed, Embase, Cochrane Library, and Web of Science for RCTs and PSM-cohorts comparing NBALS to standard medical therapy (SMT). Primary outcome was 28-day mortality; MELD-stratified subgroup analyses and random-effects meta-regression were performed. Eleven studies (comprising 12 datasets) involving 1958 patients (991 NBALS vs. 967 SMT) were included. Overall, NBALS significantly reduced 28-day mortality compared with SMT (pooled RR 0.72, 95% CI [0.63-0.83], I2 = 2.8%). Subgroup analysis suggested a clinical trend toward a distinct therapeutic window: the survival benefit was most significant in the Intermediate MELD group (25-30) (RR 0.65, 95% CI [0.52-0.81], I2 = 0%) and the High MELD group (> 30) (RR 0.75, 95% CI [0.58-0.98], I2 = 0%), while substantial uncertainty exists regarding the survival benefit in the Low MELD group (2 = 67.9%). Meta-regression confirmed that the maximum survival benefit of NBALS is concentrated within a baseline MELD range of approximately 25 to 32. Furthermore, NBALS group achieved a significantly higher reduction in total bilirubin compared to SMT (pooled MD 98.15, 95% CI [66.50-129.79], I2 = 99.2%). NBALS significantly improves short-term survival in ACLF, suggesting a potential therapeutic window around a baseline MELD range of…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,958 participants or records.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.